Compare UPLD & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPLD | XGN |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 253.9M |
| IPO Year | 2014 | 2019 |
| Metric | UPLD | XGN |
|---|---|---|
| Price | $1.51 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.50 | ★ $13.67 |
| AVG Volume (30 Days) | 181.7K | ★ 258.6K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $235,591,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $1.40 | $2.67 |
| 52 Week High | $4.98 | $12.23 |
| Indicator | UPLD | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.93 | 26.11 |
| Support Level | $1.40 | $6.37 |
| Resistance Level | $1.71 | $6.80 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 31.45 | 15.76 |
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.